When would a Yervoy (ipilimumab) generic be expected?
A true “generic” version of Yervoy would only be possible after the relevant U.S. exclusivities and patents on ipilimumab expire or are otherwise cleared. The exact timeline depends on which specific patents/exclusivities apply and whether any company successfully challenges them.
Are there any generics of Yervoy already available?
Based on the information provided here, there is not enough detail to confirm whether a Yervoy generic is already marketed or approved.
What typically determines the generic timeline for a cancer antibody like Yervoy?
For biologics such as ipilimumab, generic-style competition is usually governed by biologics regulatory pathways and patent/exclusivity protections rather than a simple “small-molecule generic” schedule. That means the timeline hinges on:
- Patent expiry on key claims tied to the drug product and manufacturing
- Any additional periods of exclusivity that delay approval
- Whether an applicant challenges patents and how those disputes resolve
How long do patent/exclusivity timelines usually take in practice?
In practice, timelines can stretch for years past initial approvals because multiple patents and exclusivities can remain in force, and litigation can delay court-ordered or regulatory approval dates.
What I need to give you an exact date
If you tell me what country you care about (U.S., EU, UK, Canada, etc.) and whether you mean “generic” strictly (chemically identical) or “biosimilar” (the usual pathway for biologics), I can map the likely dates more precisely.